{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:37Z","timestamp":1761100537408},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":110,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p>This study was undertaken to evaluate the toxicity and pharmacokinetics of a dimethyl sulphoxide (DMSO)\u2010based intravenous formulation of busulphan in the conditioning of 45 patients undergoing allogeneic or autologous stem cell transplantation (SCT). Busulphan was given as a single daily dose. In 15 patients a single dose of intravenous busulphan, given over 3\u2003h in 1\u2003d, was combined with additional oral (single daily) doses. Thirty patients received all four daily doses intravenously. Busulphan plasma levels were analysed using high performance liquid chromatography. There was no major acute toxicity with daily intravenous doses of 2\u00b78\u20133\u00b71\u2003mg\/kg infused over 3\u2003h. No veno\u2010occlusive disease (VOD) was seen in 30 patients receiving busulphan as an intravenous formulation over 4\u2003d. In the group of 15 patients receiving three oral doses and one intravenous single daily dose, one patient experienced mild VOD. Pharmacokinetic samples were taken over at least 2\u2003d of treatment in 44 patients. The area under the concentration time curve (AUC) values normalized for a dose of 1\u2003mg\/kg were 7000\u2003ng\/ml\u2003\u00d7\u2003h on d\u20031 and 5890\u2003ng\/ml\u2003\u00d7\u2003h on d\u20034, thus showing a moderate decrease over time. This was accompanied by a moderate increase of the clearance from 2\u00b76 to 3\u00b70\u2003ml\/min\/kg. Administration of busulphan as a DMSO\u2010based intravenous formulation was well tolerated. The total dose of busulphan can be given in four (rather than the typical 16) doses. With such a regimen, the intravenous administration becomes feasible on an outpatient basis.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.03044.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:37:30Z","timestamp":1047364650000},"page":"944-950","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation"],"prefix":"10.1111","volume":"114","author":[{"given":"Ulrich S.","family":"Schuler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf D.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Johne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Jenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70064-4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702590"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050404"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)83795-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(99)70007-8"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.610"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood.V85.11.3247.bloodjournal85113247","article-title":"Use of a water\u2010soluble busulphan formulation \u2013 pharmacokinetic studies in a canine model","volume":"85","author":"Ehninger G.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00694339"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558081"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686213"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":"Busulphan bioavailability","volume":"84","author":"Hassan M.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050847"},{"key":"e_1_2_6_14_1","volume-title":"Pharmacokinetic and pharmacodynamic data analysis system for the PC.","author":"Heinzel G.","year":"1993"},{"key":"e_1_2_6_15_1","first-page":"869","article-title":"Busulphan concentration in relation to permanent alopecia in recipients of bone marrow transplants","volume":"15","author":"Ljungman P.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401921"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V93.7.2196","article-title":"Increased risk of chronic graft\u2010versus\u2010host disease, obstructive bronchiolitis, and alopecia with busulphan versus total body irradiation: long\u2010term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group","volume":"93","author":"Ringden O.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_18_1","first-page":"759","article-title":"Busulphan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?","volume":"14","author":"Schuler U.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701322"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","article-title":"Busulphan pharmacokinetics using a single daily high\u2010dose regimen in children with acute leukemia","volume":"84","author":"Shaw P.J.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulphan levels on the outcome of transplantation","volume":"89","author":"Slattery J.T.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_22_1","first-page":"31","article-title":"Graft\u2010rejection and toxicity following bone marrow transplantation in relation to busulphan pharmacokinetics","volume":"16","author":"Slattery J.T.","year":"1995","journal-title":"Bone Marrow Transplantation"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.03044.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.03044.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.03044.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T14:59:56Z","timestamp":1697554796000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.03044.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1046\/j.1365-2141.2001.03044.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03044.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}